Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.35 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.34 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.35 |
| ▸ | ARNT | P27540 | 1/20 | 0.35 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31597662 | 1.00 | PTGES2 (0.42) | PTGES2ALDH1A1TDP1POLBL3MBTL1 | |
| SCHEMBL897552 | 0.98 | PTGES2 (0.44) | PTGES2ALDH1A1TDP1POLBL3MBTL1 | |
| SCHEMBL27911616 | 0.79 | PTGES2 (0.42) | PTGES2GRM4LMNAEGFRTAAR1 | |
| Hydrochloric Acid SCHEMBL670341 | 0.77 | MEN1 (0.48) | PTGES2ALDH1A1LMNAMAPTKDM4E | |
| Hydrochloric Acid SCHEMBL29502259 | 0.77 | MEN1 (0.48) | PTGES2ALDH1A1LMNAMAPTKDM4E | |
| Hydrochloric Acid SCHEMBL3651004 | 0.77 | ALDH1A1 (0.43) | PTGES2ALDH1A1TDP1POLBL3MBTL1 | |
| Hydrochloric Acid SCHEMBL29573282 | 0.77 | ALDH1A1 (0.43) | PTGES2ALDH1A1TDP1POLBL3MBTL1 | |
| Hydrochloric Acid SCHEMBL103678 | 0.77 | ALDH1A1 (0.52) | ALDH1A1TDP1POLBL3MBTL1LMNA | |
| Hydrochloric Acid SCHEMBL2522400 | 0.77 | ALDH1A1 (0.52) | ALDH1A1TDP1POLBL3MBTL1LMNA | |
| Hydrochloric Acid SCHEMBL29643719 | 0.77 | ALDH1A1 (0.52) | ALDH1A1TDP1POLBL3MBTL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114835688-B | Substituted 4-aryl imidazole-2-ketone derivative, preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2024-08-06 | — | — | CN | disclosed |
| CN-114805365-B | Factor XIA new macrocycles carrying non-aromatic P2' groups | 百时美施贵宝公司 | 2024-07-23 | — | — | CN | disclosed |
| US-11548854-B2 | Heterocyclic compounds as pesticides | BAYER CROPSCIENCE AG (DE) | 2023-01-10 | — | — | US | disclosed |
| EP-3868753-B1 | FACTOR XIA MACROCYCLIC INHIBITORS BEARING A NON-AROMATIC P2' GROUP | BRISTOL MYERS SQUIBB CO (US) | 2022-12-21 | — | — | EP | disclosed |
| CN-114835688-A | Substituted 4-aryl imidazole-2-ketone derivative and preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2022-08-02 | — | — | CN | disclosed |
| US-11332448-B2 | Heterocyclic compounds as pesticides | BAYER CROPSCIENCE AG (DE) | 2022-05-17 | — | — | US | disclosed |
| CN-113243374-B | Heterocyclic compounds as pesticides | 拜耳农作物科学股份公司 | 2022-04-26 | — | — | CN | disclosed |
| CN-108026083-B | Diamide macrocycles as factor XIA inhibitors | 百时美施贵宝公司 | 2021-08-27 | — | — | CN | disclosed |
| CN-113243374-A | Heterocyclic compounds as pesticides | 拜耳农作物科学股份公司 | 2021-08-13 | — | — | CN | disclosed |
| CN-108477173-B | Heterocyclic compounds as pesticides | 拜耳农作物科学股份公司 | 2021-07-02 | — | — | CN | disclosed |
| US-20080269293-A1 | PYRAZOLE DERIVATIVES AS ANTI-PLATELET AND ANTI-THROMBOTIC AGENTS | PFIZER INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080194668-A1 | Compounds and Compositions as Tpo Mimetics | IRM LLC (BM) | 2008-08-14 | — | — | US | disclosed |
| EP-1915341-A2 | COMPOUNDS AND COMPOSITIONS AS TPO MIMETICS | IRM, LLC (BM) | 2008-04-30 | — | — | EP | disclosed |
| EP-1910361-A2 | SUBSTITUTED TETRAHYDRO-1H-PYRIDO[4,3,B]INDOLES AS SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS | Brystol-Myers Squibb Company (US) | 2008-04-16 | — | — | EP | disclosed |
| EP-1910338-A2 | HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS | IRM, LLC (BM) | 2008-04-16 | — | — | EP | disclosed |
| WO-2008023235-A1 | PYRAZOLE DERIVATIVES AS ANTI-PLATELET AND ANTI-THROMBOTIC AGENTS | PFIZER PRODUCTS INC. (US) | 2008-02-28 | — | — | WO | disclosed |
| WO-2007022269-A2 | COMPOUNDS AND COMPOSITIONS AS TPO MIMETICS | IRM LLC (BM) | 2007-02-22 | — | — | WO | disclosed |
| WO-2007016353-A2 | SUBSTITUTED TETRAHYDRO-1H-PYRIDO[4,3,B]INDOLES AS SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-08 | — | — | WO | disclosed |
| US-20070027178-A1 | Substituted tetrahydro-1H-pyrido[4,3-b]indoles as serotonin receptors agonists and antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2007-02-01 | — | — | US | disclosed |
| WO-2007009120-A2 | HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS | IRM LLC (BM) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027178-A1 | Substituted tetrahydro-1H-pyrido[4,3-b]indoles as serotonin receptors agonists and antagonists | HTR2B, HTR1A, HTR3B | EGFR 2021/4885GAA 1854/4885PTGES2 1229/4885 |
| US-20080194668-A1 | Compounds and Compositions as Tpo Mimetics | MPL, TPO, THPO | EGFR 2871/4885GAA 1074/4885PTGES2 1099/4885 |
| US-20080269293-A1 | PYRAZOLE DERIVATIVES AS ANTI-PLATELET AND ANTI-THROMBOTIC AGENTS | P2RY1, P2RY11, P2RX7 | EGFR 4507/4885GAA 3831/4885PTGES2 1066/4885 |
| US-11548854-B2 | Heterocyclic compounds as pesticides | DDT, ACHE, PTMS | EGFR 4885/4885GAA 2146/4885PTGES2 1965/4885 |
| US-11332448-B2 | Heterocyclic compounds as pesticides | DDT, ACHE, PTMS | EGFR 4885/4885GAA 2146/4885PTGES2 1965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.